Clarithromycin in Post Covid 19 parenchymal organizing pneumonia

Not Applicable

• Conditions: Health Condition 1: J840- Alveolar and parieto-alveolar conditionsHealth Condition 2: J128- Other viral pneumonia

• Registration Number: CTRI/2020/11/029305
• Lead Sponsor: SELF DrIrfan Ismail Ayub

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. All patients diagnosed with COVID 19 based on positive result on SARS-CoV2 RT-PCR or CBNAAT from nasopharyngeal or oropharyngeal swab or secretions.

2. More than two weeks, but less than six weeks have lapsed after the above diagnostic positive result.

3. A repeat nasopharyngeal or oropharyngeal swab test (either SARS-CoV2 RT-PCR or CBNAAT) performed at two weeks or later, after earlier positive result, is now negative.

4. CT scan of thorax performed after two weeks and less than six weeks after the first positive result, shows features of organizing pneumonia.

Organizing pneumonia on CT scan of thorax is diagnosed when, one or more of the following features are identified on the CT scan images of thorax:

1.Unilateral or bilateral basal subpleural lobar, segmental or perilobular consolidation

2.Halo sign

3.Reverse halo sign or atoll sign

4.Target sign or bulls-eye sign or double halo sign

Exclusion Criteria

1.Patient is unwilling to provide consent

2.Patients with preexisting parenchymal or interstitial lung disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of patients with complete resolution of lung findings at third month of follow up.Timepoint: Three months of follow up

Secondary Outcome Measures

Name	Time	Method
Secondary objective includes percentage of patients with more than 50% reduction in the CT severity score at three months, side effect and tolerance profile of patients in the Clarithromycin arm.Timepoint: Third month of follow up. However, every two weeks, a telephone consultation will be performed to assess side effects and symptom profile and drug compliance